The following are active clinical trials which you can discuss with your healthcare team or call (631) 638-0846.
Study: E1512: A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib Cabozantinib as 2nd or 3rd Line Therapy in Patients with EGFR Wild-Type NSCLC
Principal Investigator: R. Keresztes, MD
Department:
Start Date: 6/7/13
End Date:
Study: Pfizer A7471042-1046 – A Phase 2, Multi-Cohort Study to Evaluate the Impact of Prophylactic Intervention on Dermatologic and Gastrointestinal Adverse Events and Patient Reported Outcomes in Patients Treated with Dacomitinib (PF-00299804)
Principal Investigator: R. Keresztes, MD
Department:
Start Date: 2/19/13
End Date:
Study: E5508 – Phase III Maintenance treatment with Bevacizumab, Pemetrexed, or the combination of Bevacizumab and Pemetrexed following Carboplatin, Paclitaxel & Bevacizumab for advanced Non-Squamous NSCLC – E5508 – sponsored by Eastern Cooperative Oncology Group
Principal Investigator: R. Keresztes, MD
Department:
Start Date: 9/16/10
End Date:
Study: A Phase II Study of L-BLP and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Cell Lung Cancer after Definitive Chemoradiation - E6508-Eastern Cooperative Group
Principal Investigator: R. Keresztes, MD
Department:
Start Date: 5/3/11
End Date:
Study: Open Label Randomized Phase IIIB SOC +/- Continuous Bevacizumab Treatment Beyond PHD (MO22097) (PrECOG/Roche)
Principal Investigator: R. Keresztes, MD
Department:
Start Date: 12/5/11
End Date: